<DOC>
	<DOCNO>NCT02506790</DOCNO>
	<brief_summary>This study evaluate addition melatonin metformin toremifene treatment locally advance breast cancer . Third patient receive toremifene , third receive combination melatonin toremifene patient receive combination metformin toremifene .</brief_summary>
	<brief_title>Neoadjuvant Toremifene With Melatonin Metformin Locally Advanced Breast Cancer</brief_title>
	<detailed_description>The management locally advance breast cancer complicate issue . Neoadjuvant treatment often need downstage locally advance ER positive BC tumor prior surgery . However , many patient achieve objective response treatment . The ability melatonin metformin decrease side effect chemotherapy investigate , moreover , several study confirm , drug combination conventional anti - estrogen treatment may increase objective response . But , data still controversial . We hypothesize combination melatonin metformin conventional anti - estrogen toremifene could effective toremifene alone term response rate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>Age &gt; 18 . Obtained Inform Concent . Morphologically confirm breast cancer stage IIB , IIIA , IIIB , IIIC ER positive . Eastern Collaborative Oncology Group Performance Status Scale 02 . Expected survival &gt; 6 month . Adequate liver bone marrow function . Systemic treatment breast cancer . Stage IV disease . Evidence liver bone marrow clinically meaningful disfunction . Severe uncontrolled concomitant condition disease . Pregnancy lactation . Second malignancy . Diabetes mellitus require drug therapy . Any condition preventing study participation investigator opinion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Melatonin , metformin , toremifene</keyword>
</DOC>